An interventional study of Doxylamine + Pyridoxine in Pregnancy Related and Nausea, sponsored by Valenta Pharm JSC. Completed at 1 site in Russian Federation. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Valenta Pharm JSC · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study aimed for:
644 studies on the registry are indexed under Nausea; 85 are open to participants now.
This study's enrollment of 28 is below the median of 96 across 544 interventional studies indexed under Nausea.
Browse Nausea studies →Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2
Drug: Doxylamine + Pyridoxine
Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.
Drug: Doxylamine + Pyridoxine
Drug pages: Doxylamine · Pyridoxine
A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Pharmacokinetics - Cmax (Doxylamine)
Maximum plasma concentration (Cmax)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - Cmax (Pyridoxal-5-phosphate)
Maximum plasma concentration (Cmax)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - tmax (Doxylamine)
Time to reach Cmax (tmax)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - tmax (Pyridoxal-5-phosphate)
Time to reach Cmax (tmax)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUC0-t (Doxylamine)
Area under the plasma concentration-time curve from time 0 to t (AUC0-t)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUC0-t (Pyridoxal-5-phosphate)
Area under the plasma concentration-time curve from time 0 to t (AUC0-t)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUC0-inf (Doxylamine)
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUC0-inf (Pyridoxal-5-phosphate)
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUCextr (Doxylamine)
Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - AUCextr (Pyridoxal-5-phosphate)
Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - t1/2 (Doxylamine)
Elimination half-life (t1/2)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - t1/2 (Pyridoxal-5-phosphate)
Elimination half-life (t1/2)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - kel (Doxylamine)
Elimination constant (kel)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - kel (Pyridoxal-5-phosphate)
Elimination constant (kel)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - MRT (Doxylamine)
Mean residence time (MRT)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Pharmacokinetics - MRT (Pyridoxal-5-phosphate)
Mean residence time (MRT)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of Cmax (Doxylamine)
Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of Cmax (Pyridoxal-5-phosphate)
Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of AUC0-t (Doxylamine)
Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of AUC0-t (Pyridoxal-5-phosphate)
Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of AUC0-inf (Doxylamine)
Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Bioequivalence - ratio of AUC0-inf (Pyridoxal-5-phosphate)
Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)
Safety and Tolerability: adverse event (AE) number and frequency
Number and frequency of adverse events (AEs)
Time frame: From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)
serious adverse event (SAE) number and frequency
Number and frequency of serious AEs (SAEs)
Time frame: From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: vital signs - systolic blood pressure (SBP)
SBP, mmHg
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: vital signs - diastolic blood pressure (DBP)
DBP, mmHg
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: vital signs - respiratory rate (RR)
RR, breaths per minute
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: vital signs - heart rate (HR)
HR, beats per minute
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: vital signs - body temperature
Body temperature, centigrade scale
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: physical examination results
Physical examination will follow the general rules of internal medicine: general examination, examination of mucous membranes and skin, including palpation of lymph nodes, evaluation of the musculoskeletal system, palpation, percussion, and auscultation of the main organ systems (cardiovascular, respiratory, digestive, and urinary systems) will be performed sequentially.
Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - color
Color of the urine
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - transparency
Transparency of the urine
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - pH
pH of the urine
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - specific gravity
Specific gravity of the urine
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - protein
Protein in the urine (g/L)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis - glucose
Glucose in the urine (mmol/L)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - red blood cells
Red blood cells in the urine (number in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - white blood cells
White blood cells in the urine (number in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - epithelial cells
Epithelial cells in the urine (number in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - cylinders
Cylinders in the urine (number in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - mucus
Mucus in the urine (presence in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: urinalysis (microscopy) - bacteria
Bacteria in the urine (number in sight)
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - hemoglobin
Hemoglobin, g/dL
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - red blood cells
Red blood cells, 10\^6/uL
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - hematocrit
Hematocrit, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - platelets
Platelets, 10\^3/uL
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - white blood cells
White blood cells, 10\^3/uL
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - erythrocyte sedimentation rate
Erythrocyte sedimentation rate, mm per hour
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - neutrophils
Neutrophils, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - lymphocytes
Lymphocytes, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - eosinophils
Eosinophils, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - monocytes
Monocytes, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: complete blood count - basophils
Basophils, %
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - total protein
Total protein in blood serum, g/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - creatinine
Creatinine in blood serum, umol/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - glucose
Glucose in blood serum, mmol/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - total bilirubin
Total bilirubin in blood serum, umol/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - total cholesterol
Total cholesterol in blood serum, mmol/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - alanine transaminase (ALT)
ALT in blood serum, U/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - aspartate transaminase (AST)
AST in blood serum, U/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Safety and Tolerability: blood test results - alkaline phosphatase (ALP)
ALP in blood serum, U/L
Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Sep 2022, 1 month.
Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doxylamine · Pyridoxine